OXP and anti-CD47 failed to reduce Treg content in the spleen and tumor microenvironment; this failure could be the reason why in this treatment strategy, despite an increase in CD8+ T cells, we didn't see the therapeutic response. This evidence concerns the gene CD47 and neoplasm.